Company intelligence / Profile preview
Adial Pharmaceuticals, Inc.
Glen Allen, Virginia, United Statesadial.com ↗
- Ownership
- Public · ADIL
- Employees
- ~9
- Development stage
- Other
01
Overview
Completed ONWARD Phase 3 trial for AD04 in 2022 with promising results in reducing drinking in heavy drinking patients with no overt safety or tolerability concerns. Currently conducting a pharmacokinetics study of AD04 with topline results expected in Q4 2024, preparing for another Phase 3 trial.
- Therapeutic areas
- PsychiatryEndocrinology
- Modalities
- Small moleculesSerotonin-3 receptor antagonist
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Financials
- Market cap
- $5.8M
- Total revenue
- $0
- Enterprise value
- $-23M
Beyond the preview
Go deeper on Adial Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adial Pharmaceuticals, Inc..